Tagged with China

China China has expanded to be the second largest pharmaceutical market globally with USD 137 billion in total spending in 2018, but growth has slowed from a 19% CAGR in 2008–2013 to an 8% CAGR in 2013–2018 and is expected to continue to decline to 3-6% through 2023, as the below…

China Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein engineering and their mission to become a highly differentiated oncology biotech company, and Alphamab’s dual China-US development strategy in support…

China Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative commercial partnerships he has established with leading health insurance companies in China.   My medical knowledge is limited. But I…

China Dr Yangzhou Wang, chief operations officer of Crown Bioscience (CrownBio), shares the new era of development for the company following its acquisition by a Japanese industrial conglomerate in December 2017; CrownBio’s biology-driven deep expertise in oncology drug discovery and development and how it will continue to drive the company’s growth;…

China In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s effect on pricing stands to hit domestic generic firms hardest unless they adapt their business models. Big Pharma could also lose out as their off-patent originators…

China Adam Dunnett, secretary general of the European Union Chamber of Commerce in China (European Chamber) outlines the organization’s three key roles of advocacy, providing business intelligence and strengthening the European business community. He also details an extraordinarily productive past six months – during which the European Chamber held meetings with…

China Andras Gizur, president China & APAC for Gedeon Richter, shares his insights on the current market environment in China following the spate of recent healthcare reforms, the exciting innovations Gedeon Richter plans to launch in China in the next few years, the importance of fostering a friendly, cooperative and stable…

China Davide Dalle Fusine, general manager for Chiesi China, shares the key milestones for the company in the past five years, their leadership position in neonatology and strength respiratory franchise in China, the importance of the Chinese market for global operations, as well as his strategic priorities for the next few…

China Pierre Faury, co-President of the French Healthcare Alliance in China as well as vice-President of Sanofi China in charge of Commercial Excellence, shares the mandate of the French Healthcare Alliance and its objective to bring together French companies in China, in collaboration with the French Embassy, to support the development…

China Tony Au, general manager of AbbVie China, shares the key milestones for the affiliate in the past six years, the strong foundation he has built for AbbVie in China, the mission of AbbVie to be the most reliable pharmaceutical company in China, and the exciting pipeline of innovative products and…

China China is set to become the second largest market for Mundipharma’s OxyContin behind the US.   It comes as no surprise that sales of opioids such as OxyContin have plummeted in the US following the media storm around the opioid crisis that sees the loss of thousands of American lives…

China Dr Dan Zhang, CEO of Fountain Medical Development (FMD), details the transformation China’s recent membership at the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) will bring to the drug development and clinical research landscape in China, the pressures and opportunities local companies…